Wegovy 4 mg pill self-pay price rises to $199 as $149 intro offer ends

People who pay cash for the 4 mg Wegovy tablet (semaglutide) now pay $199 a month. The $149 introductory price for that dose ended on August 31, 2026, according to Novo Nordisk's Wegovy cost and coverage page ^[1] and the NovoCare price guide ^[2].

The company had offered $149 a month for both the 1.5 mg and 4 mg tablet doses. The 4 mg offer was described as available only until August 31, 2026, after which the price would be $199 per month ^[1]. The price guide now lists the standard self-pay price for the 4.0 mg pill at $199 a month and the 1.5 mg pill at $149 a month ^[2]. The 9 mg and 25 mg pills are listed at $299 a month each ^[2].

The change applies only to the 4 mg dose. Self-pay pricing varies by dose across the Wegovy lineup, and the higher pill strengths were not part of the $149 introductory offer ^[1][2].

Once a patient reaches the 9 mg or 25 mg pill, a separate subscription program offers lower monthly prices. Novo Nordisk launched that program on March 31, 2026, through telehealth providers including Ro, WeightWatchers, LifeMD, Hims & Hers and Sesame. It offers 3-, 6- and 12-month terms. For the 9 mg and 25 mg pills, the listed prices are $289 a month for 3 months, $269 for 6 months and $249 for 12 months, which the company says amounts to savings of up to $600 a year on the pill ^[3]. Novo Nordisk said the limited-time offers are separate and are not included in the subscriptions ^[3].

Injection pricing is unchanged by the expiration. The company lists the 0.25 mg and 0.5 mg Wegovy pen at $199 a month for the first two months for patients new to the savings offer or NovoCare Pharmacy, then $349 a month. The 1 mg, 1.7 mg and 2.4 mg pen doses are listed at $349 a month, and the Wegovy HD 7.2 mg pen at $399 a month ^[1][2]. The pen introductory offer runs for two monthly fills through December 31, 2026 ^[1].

For people with commercial insurance, the company lists a copay of as little as $25 a month, subject to a maximum savings of $100 a month, with government beneficiaries excluded ^[1][2]. For eligible Medicare Part D beneficiaries, the Medicare GLP-1 Bridge program offers all dose strengths of both the Wegovy pen and pill for $50 a month from July 1, 2026, through December 31, 2027 ^[1].

Why it matters for patients

For someone paying cash for the 4 mg tablet, the monthly cost rose by $50, or about $600 over a year if the price stays at $199 ^[1][2]. Because the increase applies to one dose and not others, the amount a person pays can change as their prescribed strength changes, and the entry-level $149 price now applies to the 1.5 mg pill only ^[2].

Other options listed by the manufacturer, such as insurance copays, the savings offer, the telehealth subscription and the Medicare bridge program, carry their own eligibility rules, and Novo Nordisk states it reserves the right to modify or cancel these programs at any time ^[1][2]. Wegovy's patient materials suggest that people paying at a retail pharmacy ask their pharmacist to compare all pricing options, including whether insurance covers the prescription, whether the savings offer applies, and what the self-pay price would be at their current dose ^[1].

What happens next

The $149 price for the 1.5 mg pill and the $299 price for the 9 mg and 25 mg pills remain in the published price guide ^[2]. The pen introductory offer for the 0.25 mg and 0.5 mg doses runs through December 31, 2026 ^[1], and the Medicare bridge program runs through December 31, 2027 ^[1]. Whether the 4 mg pill price will change again, and whether Novo Nordisk will extend any introductory offers to other doses, has not been reported.